Baltimore facility key to Emergent's plan to expand beyond biodefense

Steven Overly, Washington Post, July 19, 2010 Rockville-based Emergent BioSolutions is planning to make major renovations to a 55,000-square-foot facility in Baltimore that the pharmaceutical company said is key to its plans to expand beyond the biodefense sector. Known as the producer of the only FDA-approved anthrax vaccine, Emergent executives said the company aims to remain competitive by expanding the number and variety of drugs it has on the market. "We're well positioned to maintain our leadership" in anthrax vaccination, said Kyle Keese, senior vice president for manufacturing operations. ... Baltimore